Better Health for All

The company focuses on specialized pharmaceutical treatments for rare and underserved medical conditions, including urology and ADHD, with 3 FDA-approved products.

Its products aim to improve health outcomes, and there is no evidence of revenue from products with established negative health outcomes. The company reported a 78% clinical success rate in targeted therapies. However, its products, Natesto and Adzenys, have average monthly prices of $1,200 and $850 respectively, and a price premium of 15-20% compared to generic alternatives. A patient assistance program supports 65% of eligible patients up to $15,000, and patient accessibility rates are 70-80% with tiered or volume-based pricing. The company focuses on underserved medical conditions but provides no specific data on access for vulnerable populations. In 2023, the company's R&D expenditure was $14.3 million, with $8.7 million invested in clinical trials. The company engages with medical professionals through conferences, meetings, and webinars, and provides online resources for patients. The company holds patents for rare disease therapeutics (expiring 2028-2036) and urology treatment technologies (expiring 2029-2034).

Fair Money & Economic Opportunity

Aytu BioPharma, Inc. is a specialty pharmaceutical company. The value 'Fair Money & Economic Opportunity' assesses activities related to lending, insuring, moving, or storing money, and how financial institutions democratize access to fair financial services. The company's core business lies outside financial services. While Aytu BioPharma offers patient assistance programs, such as RxConnect, which provide financial support for medication costs (e.g., 65% coverage for eligible patients, up to $15,000 per patient, and 75% insurance negotiation support), these initiatives are focused on pharmaceutical product access and affordability, not on providing financial products or services to consumers or businesses.

Therefore, all KPIs related to financial services are not applicable to the company's operations.

Fair Pay & Worker Respect

Employee sentiment indicates that 39% of employees would recommend working at Aytu.

Overall employee ratings on Glassdoor are 3.0 out of 5 stars, with specific ratings of 2.6/5 for compensation and benefits, 2.9/5 for senior management, and 2.7/5 for career opportunities. Employee reviews frequently mention low base pay compared to competitors, poor management decisions, and inconsistent communication.

Fair Trade & Ethical Sourcing

No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. While the company declares compliance with internal programs

and expects ethical behavior from business partners , there is no data on fair-trade certifications, supplier audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, high-risk materials spend, or supplier diversity spend.

Honest & Fair Business

The company has a formal whistleblower policy that explicitly states there will be no retaliation for good-faith complaints.

It provides a confidential ethics hotline (1-844-TELL-AYTU), website, and email, with contact options including the CEO, CFO, Audit Committee Chair, and outside counsel. The CEO and Senior Financial Officers are required to report material information affecting disclosures, internal control deficiencies, fraud, conflicts of interest, or violations of securities laws or the Code of Conduct to the Audit Committee. The company has an anti-corruption policy that addresses potential violations of the FCPA (Foreign Corrupt Practices Act) and emphasizes avoiding conflicts of interest. An insider trading policy, effective July 1, 2021, applies to all employees, officers, directors, consultants, and contractors, prohibiting trading on material non-public information and during black-out periods. The company's policy mentions the potential use of outside counsel and/or financial/forensic auditing companies for investigations, but this is not explicitly tied to independent verification of ethical claims, and no specific percentage of claims verified is provided.

Kind to Animals

Aytu BioPharma, Inc. conducts animal testing for medical analysis and clinical research purposes.

The provided articles do not offer specific data points for other KPIs, such as the percentage of cruelty-free certified products, the number of animals used annually, details of any animal testing policy, or investment in animal-free alternatives.

No War, No Weapons

No specific, concrete evidence was found in the provided articles to assess AYTU.US against any of the KPIs for the 'No War, No Weapons' ethical value. The articles describe the company as a specialty pharmaceutical firm and detail its general ethical conduct, compliance programs, and ESG committee charters.

However, they do not provide explicit facts or quantitative data regarding arms contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other metrics directly related to military or conflict involvement.

Respect for Cultures & Communities

The provided articles, including those from ditchcarbon.com, LinkedIn, and Aytu BioPharma's investor relations, focus on carbon footprint

, career opportunities , or the establishment of an ESG Committee Charter. None of the articles contain specific quantitative data or details regarding Aytu BioPharma's performance or initiatives related to formal partnerships with community groups, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license to operate, charitable giving for cultural heritage, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.

Safe & Smart Tech

Aytu BioPharma received an FDA warning letter on September 9, 2025, for misbranding a product due to false or misleading sponsored links and failing to include the established name of the drug in these links.

This indicates a severe lack of algorithmic transparency, as public-facing promotional content was found to be misleading. The company also failed to submit these promotional materials to the FDA as required, demonstrating basic compliance with major regulations but with gaps. Furthermore, Aytu BioPharma's privacy policy, last updated March 22, 2025, states that users have the right to ensure their personal data is up-to-date and, in some countries, the legal right to require correction or deletion, with inquiries directed to info@aytubio.com. This suggests moderate data control options with potential friction in exercising rights due to geographical limitations and reliance on email for requests.

Zero Waste & Sustainable Products

The provided articles do not contain any specific, quantitative data points or factual evidence related to Aytu BioPharma's performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

While one article notes "Waste" as a negative impact category in a general ESG assessment, it does not provide any measurable data to score against the specific KPIs in the rubric.